Latest Gonadotropin-releasing hormone antagonist Stories
Giving women gonadotrophin-releasing hormone (GnRH) antagonists leads to similar live-birth rates compared with GnRH agonists, according to a new study.
ABBOTT PARK, Ill. and SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain.
SAN FRANCISCO, June 1 /PRNewswire/ -- FIRMAGONÂ® (degarelix for injection) resulted in fast, long-term suppression of testosterone in prostate cancer patients, without an initial testosterone surge or microsurge, and rapidly reduced prostate-specific antigen (PSA) levels, according to a review of data presented here today at the AUA 2010 annual meeting by Dr.
WALTHAM, Mass., Feb.
WHITEHOUSE STATION, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, today announced the European Commission (EC) approval of ELONVAÂ® (corifollitropin alfa injection).
WHITEHOUSE STATION, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Merck & Co., Inc.
ATLANTA, Oct. 20 /PRNewswire/ -- Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPURÂ® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist.
Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study AMSTERDAM, July 1 /PRNewswire-FirstCall/ -- Schering-Plough Corp., (NYSE: SGP) today announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating...
SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
Post-Treatment Segment of Elagolix Petal Study Confirms Previous Positive Findings on Efficacy and Safety Neurocrine to Present These Additional Study Results at Deutsche Bank 34th Annual Healthcare Conference Today at 5:05pm Eastern Time SAN DIEGO, May 18 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc.
- A handkerchief.
- In general, any miraculous portrait of Christ.